Experts on Lp(a) testing, statin myths, cognitive safety, and the 2025-2030 Dietary Guidelines share counseling points from the National Lipid Association's Fall Clinical Lipid Update meeting.
|Articles|May 13, 2016
The Fight for Transparency in LTC Pharmacy Benefit Management
True North talks about the Senior Care Pharmacy Coalition, pharmacy benefit managers, and ongoing long-term care pharmacy trends and issues with Alan Rosenbloom, who is the president and CEO of the Senior Care Pharmacy Coalition.
Advertisement
True North talks about the Senior Care Pharmacy Coalition, pharmacy benefit managers, and ongoing long-term care pharmacy trends and issues with Alan Rosenbloom, who is the president and CEO of the Senior Care Pharmacy Coalition.
Advertisement
Related to this article
At-home chemotherapy for HR+ breast cancer works best when pharmacists guide oral regimens, boosting adherence, safety, and affordable access.
Managing medication safety in specialized populations requires a shift from standardized dosing to precise, patient-specific customization.
Emergency and ICU pharmacists would be most likely to see pneumonic plague. An expert reviews first-line agents, alternatives, and postexposure prophylaxis.
A former residency program director unpacks why this debate keeps resurfacing, and why some reasons people give for skipping residency may not hold up the way they think they do.
Eric Lawitz, MD, explains how pharmacists can discuss liver risk with patients with obesity and why a FIB-4 score from routine blood work is a good first step.
Pharmacogenomic-guided prescribing uses genetic data to protect patients from dangerous toxicities and get them the right drug at the right dose from the start.
As accessible health care providers, pharmacists can raise awareness about the proper use of OTC blood glucose meters and continuous glucose monitoring devices.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Preparing Pharmacists for Psychedelic Medicine
2
Pneumonic Plague: What Pharmacists Need to Know About Treatment
3
FDA Approves Pritelivir for Refractory HSV Lesions in Immunocompromised Adults
4
FDA Approves First Once-Monthly Subcutaneous Olanzapine LAI for Adults With Schizophrenia
5